Figure 6.

Effect of KRT15 expression on OS and DSS based on data obtained from The Cancer Genome Atlas. (A) The 300-month OS rate of patients with BRCA and high KRT15 expression was significantly higher compared with that in the low KRT15 expression group (P=0.001; HR=0.58; 95% CI, 0.42-0.81). (B) The 300-month DSS rate in patients with BRCA and high KRT15 expression was significantly higher compared with that of patients with low KRT15 expression (P=0.005; HR=0.53; 95% CI, 0.33-0.83). DSS, disease-specific survival; OS, overall survival; BRCA, breast invasive carcinoma; KRT15, keratin 15; HR, hazard ratio; CI, confidence interval.